← Back to Search

Mitotic Inhibitor

rebastinib for Solid Tumors

Phase 1 & 2
Waitlist Available
Research Sponsored by Deciphera Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female patients ≥18 years of age at the time of informed consent.
Part 1 Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor for which paclitaxel is considered appropriate treatment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 36 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug, rebastinib, to see if it is safe and effective when combined with another cancer drug, paclitaxel.

Eligible Conditions
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events (Part 1 and Part 2)
Objective response rate (ORR) (Part 2)
Secondary outcome measures
Area under the concentration-time curve (AUC) of rebastinib
Duration of response (DOR)
Maximum observed concentration (Cmax) of rebastinib
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part 2Experimental Treatment2 Interventions
Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with paclitaxel Triple-negative and Stage IV inflammatory breast cancer Ovarian cancer Endometrial cancer Gynecological Carcinosarcoma
Group II: Part 1 - CompletedExperimental Treatment2 Interventions
Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rebastinib
Not yet FDA approved
Paclitaxel
FDA approved

Find a Location

Who is running the clinical trial?

Deciphera Pharmaceuticals LLCLead Sponsor
16 Previous Clinical Trials
2,067 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
2018. "A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03601897.
~28 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top